New Stents On The Block: Innovators Look Beyond Drug Coatings
This article was originally published in The Gray Sheet
Executive Summary
Several small start-ups are vying to steal the spotlight from the major coronary stent makers with novel stent designs and surface coatings that have clinicians taking note
You may also be interested in...
TCT In Brief
PREPARE: St. Jude Medical's Proxis embolic protection device helps to resolve ST-segment elevation faster in patients with ST-elevated myocardial infarction, according to results of the 280-patient Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients with Acute Myocardial Infarction Undergoing Primary PCI (PREPARE) trial, presented at the Transcatheter Cardiovascular Therapeutics scientific symposium on Oct. 15 by Karel Koch, University of Amsterdam. ST elevation refers to the electrocardiographic signal associated with impending infarction. In PREPARE, ST-elevation was immediately resolved in 66% of the patients randomized to percutaneous coronary intervention with embolic protection from Proxis, compared to 50% of patients treated with PCI without embolic protection. After 30 minutes, 75% of Proxis patients and 66% of control patients were out of ST-elevation. There were no complications with Proxis, which was 510(k)-cleared in 2003
OrbusNeich Says “Bio-Engineered” Stent May Be Solution To Thrombosis Risk
OrbusNeich hopes to lead a new wave of stent technology with its Genous Bio-engineered R-Stent, which the firm says is safer than existing drug-eluting stents because it has a natural antibody coating instead of a drug-eluting polymer
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.